Joint Corp. sees FY19 revenue up 26%-32%, consensus $40.72M
Adjusted EBITDA to grow between 67% and 100%, compared to $2.9 million in 2018 and Company-owned or managed clinic expansion, through a combination of both greenfields and buybacks, to range from 8 to 12.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.